Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

July 9, 2013

Plandai Primed To Fight Colon Cancer

Much has been written about colon cancer prevention and treatment. Still, the prognosis for those diagnosed with colon cancer remains poor. In fact, colon cancer is now one of the most deadly forms of cancer in the world.  The American Cancer Society estimates that this year 142,820 people will be diagnosed with and that 50,830 will die from colon cancer in the United States.  The disease is the third most commonly diagnosed cancer and the second leading cause of cancer death in the U.S. Amazingly, the risk of developing colon cancer is about one in five.  Nonetheless, studies have shown that certain substances and nutrients may be beneficial to fighting colon cancer--if absorption rates can be increased. Plandai Biotechnology, Inc. (OTCQB – PLPL - $0.52 – Spec Buy) appears poised to fill this unmet need.

Carotenoids are substances found in fruits that give them their respective bright colors, such as tomatoes and oranges.  In a number of studies and tests, carotenoids have demonstrated an ability to provide nutrients beneficial in fighting colon cancer.  For example, Lutein, a compound that is found in 600 or so naturally occurring carotenoids, has shown to have the greatest effect in the fight.  Data from several American Journal of Medicine studies have demonstrated that subjects who incorporated meaningful quantities of carotenoid and lutein foods into their diet such as spinach, broccoli, lettuce, tomatoes, oranges, orange juice, carrots, celery, and greens have been clearly aided in reducing their risk of developing colon cancer.

Plandaí’s Phytofare Carotenoid Botanical Extract is a unique product that harnesses the beneficial effects of these nutrients due to the Company’s unique and advanced extraction process and absorption into the circulatory system which enables absorption and bioavailability many times greater than other extraction and delivery systems. Therefore, this extract could potentially emerge as the carotenoid extract of choice for manufacturers in the nutraceutical and foods arenas.

As part of the Company’s objective of producing and marketing highly bioavailable ingredients that have proven benefits to immune health and the prevention of diseases and conditions, the Company plans to market this product sometime in 2014. This is good news not just for the health conscience consumer, but for those actively seeking to use products that offer the greatest absorption rate in their quest to prevent the onset of disease and cancer.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. 

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.